ASH 2020 | Enasidenib plus azacitidine in newly-diagnosed AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the findings from a Phase II/Ib sub-study that is part of the Beat AML study group. The study investigated the efficacy of treating newly-diagnosed IDH2-mutant AML patients with enasidenib (ENA) monotherapy, a selective IDH2 inhibitor, followed by response-driven addition of azacitidine (aza). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Eytan Stein, MD, has done consultancy for Amgen, Agios Pharmaceuticals, Celgene Pharmaceuticals, Abbvie, Seattle Genetics, Syndax, Genentech, Biotheryx, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; has participated in a board of directors or advisory committee with Agios Pharmaceuticals, Celgene Pharmaceuticals, Genentech, Syros, PTC Therapeutics, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; and has received research funding from Celgene Pharmaceuticals, Syndax, Bayer, Novartis and Daiichi-Sankyo.
